期刊文献+

RDEA3170的合成工艺研究 被引量:3

Synthesis of RDEA3170
原文传递
导出
摘要 目的寻找一条合成尿酸转运体1(URAT1)抑制剂RDEA3170的实用的合成路线。方法利用3-溴-4-氯吡啶和1,4-二溴萘作为起始原料来合成RDEA3170,并着重研究1,4-二溴萘合成4-溴-1-萘腈(3)、化合物3合成(4-氰基萘-1-基)硼酸(4)和Suzuki偶合3步关键反应的反应条件。结果经6步反应合成了RDEA3170,并利用MS和1H-NMR确证了结构,此路线总收率为16%;同时得到了上述3个关键步骤的最优化的反应条件。结论得到了一条合成RDEA3170的实用路线。 Objective To find a practical synthetic route of uric acid transporter 1(URAT1) inhibitor RDEA3170. Methods 3-Bromo-4-chloropyridine and 1,4-dibromonaphthalene were used as starting materials. Three key synthetic steps, synthesis of 4-bromo-1-naphthonitrile(3), synthesis of(4-cyanonaphthalen-1-yl)boronic acid(4) from compound 3, and the Suzuki coupling, were studied for the optimal reaction conditions. Results RDEA3170 was synthesized by 6 steps. The target compound was synthesized and characterized by MS, and 1H-NMR. The overall yield of this route was 16%. The reaction conditions of the three key steps were optimized. Conclusion A practical synthetic route of RDEA3170 is obtained.
出处 《现代药物与临床》 CAS 2015年第10期1179-1184,共6页 Drugs & Clinic
基金 国家自然科学基金资助项目(21302141) 天津市应用基础与前沿技术研究计划项目(14JCQNJC12900)
关键词 RDEA3170 lesinurad URAT1抑制剂 合成工艺 高尿酸血症 痛风 RDEA3170 lesinurad URAT1 inhibitor synthetic technology hyperuricemia gout
  • 相关文献

参考文献16

  • 1Punzi L, Scanu A, Ramonda R, et al. Gout as autoinflammatory disease:new mechanisms for more appropriated treatment targets[J]. Autoimmun Rev, 2012, 12(1):66-71.
  • 2Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels[J]. Nature, 2002, 417(6887):447-452.
  • 3Burns C M, Wortmann R L. Gout therapeutics:new drugs for an old disease[J]. Lancet, 2011, 377(9760):165-177.
  • 4Singh J A. Emerging therapies for gout[J]. Expert Opin Emerg Drugs, 2012, 17(4):511-518.
  • 5Moyle G, Boffito M, Stoehr A, et al. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects[J]. Antimicrob Agents Chemther, 2010, 54(8):3170-3178.
  • 6耿艳艳,于冰,徐为人,汤立达.新型痛风治疗药物lesinuard sodium[J].现代药物与临床,2014,29(6):685-689. 被引量:17
  • 7田禾,蔡文卿,谢亚非,刘钰强,魏鹏,高志刚,汤立达,徐为人,赵桂龙.lesinurad的合成工艺研究[J].现代药物与临床,2015,30(1):1-7. 被引量:7
  • 8Diaz-Torné C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout[J]. Curr Opin Rheumatol, 2015, 27(2):164-169.
  • 9Ardea Biosciences Inc. Thioacetate compounds, compositions and methods of use[P]. US:20130281469, 2013-10-24.
  • 10Ardea Biosciences Inc. 3,4-Disubstituted pyridine compounds, methods of using and compositions comprising the same[P]. WO:2013067425, 2013-05-10.

二级参考文献34

  • 1Michael D, Jansen T L, George N, et al. Gout: why is this curable disease so seldom cured [J]. Ann Rheum Dis, 2012, 71(11): 1765-1770.
  • 2Pema K M. lesinuard sodium [J]. Drugs Fut, 2011, 36(12): 875.
  • 3Yeh L, Hingorani V, Manhard K, et al. Safety and uric acid lowering effect in humans following multiple doses of RDEA806, a novel prodrug for the potential treatment of hyperuricemia [J]. Ann Rheum Dis, 2008, 67: 248.
  • 4Yeh L, Tamai I, Hamatake R, et al. Mode of action of RDEA594 as a uric acid lowering agent in humans following multiple doses of its prodrug RDEA806 [J]. Ann Rheum Dis, 2008, 67(Suppl Ⅱ): 249.
  • 5Enomoto A, Kimura H, Chairoungdu A, et al. Molecular identification of a renal urate anion exchanger thatregulates blood urate levels [J]. Nature, 2002, 17: 447-452.
  • 6Endou H, Anzai N. Urate transport across the apical membrane of renal proximal tubules [J]. Nucleosides Nucleotides Nucleic Acids, 2008, 27(6): 578-584.
  • 7Hagos Y, Stein D, Ugele B, et al. Human renal organic anion transporter 4 operates as an asymmetric urate transporter [J]. JAm Soc Nephrol, 2007, 18(2): 430-439.
  • 8Yeh L T, Shen Z, Kerr B, et al. RDEA594, a potent URAT1 inhibitor without affecting other important renal transporters OAT1 and OAT3 [J]. Ann Rheum Dis, 2009, 68(Supp13): 320.
  • 9Yang X Q, Dick R, Borges V, et al. Evaluation of drug-drug interaction potential between RDEA594, allopurinol and febuxostat in preclinicalspecies [J]. Arthritis Rheum, 2009, 60: 412-413.
  • 10Yeh L, Yang J, Theiss J, et al. RDEA594, a potential uric acid lowering agent through inhibition of uric acid reuptake, shows better pharmacokinetics than its prodrug RDEA806 [C]. San Francisco: 2008 Annual Scientific Meeting, 2008.

共引文献19

同被引文献13

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部